Tyra Biosciences

TYRA BIOSCIENCES INC

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFRM

INCY

KMDA

NEOG

OMER

TSLA

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Stock Movers

ACON

DRCT

DTIL

INUV

KULR

LGCB

NAOV

PLAG

POLA

QUBT

REVB

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

CELC

NMRA

PKST

XPEV

Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Tyra Biosciences Inc

TYRANNA RESOURCES LTD by Tyranna Resources Ltd.

Tyranna Resources Ltd

Press Releases

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Earnings

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

HC Wainwright & Co.

Wedbush

B of A Securities

Oppenheimer

Comments

Tyra Biosciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga